358 related articles for article (PubMed ID: 31146489)
41. Identification of a 3-gene signature based on differentially expressed invasion genes related to cancer molecular subtypes to predict the prognosis of osteosarcoma patients.
Wan Y; Qu N; Yang Y; Ma J; Li Z; Zhang Z
Bioengineered; 2021 Dec; 12(1):5916-5931. PubMed ID: 34488541
[TBL] [Abstract][Full Text] [Related]
42. A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma.
Zheng Y; Xu J; Lin J; Lin Y
Comput Math Methods Med; 2022; 2022():8003525. PubMed ID: 35844445
[TBL] [Abstract][Full Text] [Related]
43. Application of Long Noncoding RNAs in Osteosarcoma: Biomarkers and Therapeutic Targets.
Li Z; Dou P; Liu T; He S
Cell Physiol Biochem; 2017; 42(4):1407-1419. PubMed ID: 28715796
[TBL] [Abstract][Full Text] [Related]
44. An Immunohistochemical Study of Stathmin 1 Expression in Osteosarcoma Shows an Association with Metastases and Poor Patient Prognosis.
Zhao C; Li H; Wang L; Sun W
Med Sci Monit; 2018 Aug; 24():6070-6078. PubMed ID: 30169496
[TBL] [Abstract][Full Text] [Related]
45. Development of a novel prognostic signature of long non-coding RNAs in lung adenocarcinoma.
Zheng S; Zheng D; Dong C; Jiang J; Xie J; Sun Y; Chen H
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1649-1657. PubMed ID: 28409273
[TBL] [Abstract][Full Text] [Related]
46. Identification and Validation of a Potent Multi-miRNA Signature for Prediction of Prognosis of Osteosarcoma Patients.
Luo X; Tang J; Xuan H; Liu J; Li X
Med Sci Monit; 2020 Feb; 26():e919272. PubMed ID: 32098942
[TBL] [Abstract][Full Text] [Related]
47. Down-regulation of microRNA152 is associated with the diagnosis and prognosis of patients with osteosarcoma.
Wang NG; Wang DC; Tan BY; Wang F; Yuan ZN
Int J Clin Exp Pathol; 2015; 8(8):9314-9. PubMed ID: 26464682
[TBL] [Abstract][Full Text] [Related]
48. LncRNA SOX2-OT is a novel prognostic biomarker for osteosarcoma patients and regulates osteosarcoma cells proliferation and motility through modulating SOX2.
Wang Z; Tan M; Chen G; Li Z; Lu X
IUBMB Life; 2017 Nov; 69(11):867-876. PubMed ID: 28960757
[TBL] [Abstract][Full Text] [Related]
49. Development and validation of apoptosis-related signature and molecular subtype to improve prognosis prediction in osteosarcoma patients.
Hong J; Li Q; Wang X; Li J; Ding W; Hu H; He L
J Clin Lab Anal; 2022 Jul; 36(7):e24501. PubMed ID: 35576501
[TBL] [Abstract][Full Text] [Related]
50. A novel lncRNA-focus expression signature for survival prediction in endometrial carcinoma.
Zhou M; Zhang Z; Zhao H; Bao S; Sun J
BMC Cancer; 2018 Jan; 18(1):39. PubMed ID: 29304762
[TBL] [Abstract][Full Text] [Related]
51. Identification of N6-methylandenosine related LncRNAs biomarkers associated with the overall survival of osteosarcoma.
Zhang P; Xu K; Wang J; Zhang J; Quan H
BMC Cancer; 2021 Dec; 21(1):1285. PubMed ID: 34852770
[TBL] [Abstract][Full Text] [Related]
52. Circadian rhythm-associated lncRNA RP11-414H17.5 as a key therapeutic target in osteosarcoma affects the tumor immune microenvironment and enhances malignancy.
Huang L; Liang W; Cai W; Peng H
J Orthop Surg Res; 2023 Dec; 18(1):947. PubMed ID: 38071320
[TBL] [Abstract][Full Text] [Related]
53. Tissue microRNA-126 expression level predicts outcome in human osteosarcoma.
Liu W; Zhao ZY; Shi L; Yuan WD
Diagn Pathol; 2015 Jul; 10():116. PubMed ID: 26194657
[TBL] [Abstract][Full Text] [Related]
54. Decreased expression of STAT5A predicts poor prognosis in osteosarcoma.
Guo Z; Tang Y; Fu Y; Wang J
Pathol Res Pract; 2019 Mar; 215(3):519-524. PubMed ID: 30638860
[TBL] [Abstract][Full Text] [Related]
55. A risk assessment model for the prognosis of osteosarcoma utilizing differentially expressed lncRNAs.
Sun K; Zhao J
Mol Med Rep; 2019 Feb; 19(2):1128-1138. PubMed ID: 30569146
[TBL] [Abstract][Full Text] [Related]
56. Development of a novel immune-related genes prognostic signature for osteosarcoma.
Wu ZL; Deng YJ; Zhang GZ; Ren EH; Yuan WH; Xie QQ
Sci Rep; 2020 Oct; 10(1):18402. PubMed ID: 33110201
[TBL] [Abstract][Full Text] [Related]
57. Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma.
Wang Z; Cai H; Lin L; Tang M; Cai H
Pediatr Blood Cancer; 2014 Feb; 61(2):206-10. PubMed ID: 24038809
[TBL] [Abstract][Full Text] [Related]
58. Pseudogene MSTO2P enhances hypoxia-induced osteosarcoma malignancy by upregulating PD-L1.
Shi C; Huang CM; Wang B; Sun TF; Zhu AX; Zhu YC
Biochem Biophys Res Commun; 2020 Oct; 530(4):673-679. PubMed ID: 32768186
[TBL] [Abstract][Full Text] [Related]
59. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma.
Zhao QJ; Zhang J; Xu L; Liu FF
World J Gastroenterol; 2018 Aug; 24(30):3426-3439. PubMed ID: 30122881
[TBL] [Abstract][Full Text] [Related]
60. Combined over-expression of the hypoxia-inducible factor 2α gene and its long non-coding RNA predicts unfavorable prognosis of patients with osteosarcoma.
Li W; He X; Xue R; Zhang Y; Zhang X; Lu J; Zhang Z; Xue L
Pathol Res Pract; 2016 Oct; 212(10):861-866. PubMed ID: 27623205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
